The Latest Breaking News from Medtronic

FDA Approves Medtronic's Recharge-Free Sacral Nerve Stimulation Therapy For Bladder, Bowel Control

The FDA has approved Medtronic plc's (NYSE:

Benzinga · Feb 23, 2022

Medtronic's Q3 Profit In Line With Expectation Despite COVID-19 Impact On Procedure Volume

Medtronic Plc's (NYSE: MDT) Q3 FY22 sales of $7.76

Benzinga · Feb 22, 2022

Recap: Medtronic Q3 Earnings

  Medtronic (NYSE:MDT) reported its Q3 earnings results on Tuesday, February 22, 2022 at 06:45 AM. Here's what investors need to know about the announcement.

Benzinga · Feb 22, 2022

Medtronic Issues Voluntary Recall For TurboHawk Plus Directional Atherectomy System

Medtronic Plc (NYSE: MDT) has initiated a voluntary recall to customers related to the risk associated with tip damage caused by guidewire prolapse in its 6 French (6Fr) TurboHawk Plus Directional Atherectomy System.

Benzinga · Feb 7, 2022

Analyst Ratings For Medtronic

Analysts have provided the following ratings for Medtronic (NYSE:MDT) within the last quarter:

Benzinga · Jan 25, 2022

10 Biggest Price Target Changes For Tuesday

Needham cut Medtronic plc (NYSE: MDT) price target from $131 to $128. Medtronic shares fell 0.7% to $103.44 in pre-market trading.

Benzinga · Jan 25, 2022

Medtronic Recalls HawkOne Atherectomy System Due To Tip Damage Risk

Medtronic Inc (NYSE: MDT) is recalling HawkOne Directional Atherectomy System due to the risk of the guidewire within the 

Benzinga · Jan 21, 2022

FDA: Medtronic slow to update, recall defective insulin pumps for diabetes patients

While the U.S. Food and Drug Administration acknowledges Medtronic is actively working on fixing issues within its diabetes business, especially in regard to some of its insulin pumps, it says the steps took too long and are not enough.

Tribune News Service · Jan 17, 2022